Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

Published:2014-12 Issue:13 Volume:15 Page:1460-1468
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sestak Ivana,Singh Shalini,Cuzick Jack,Blake Glen M,Patel Rajesh,Gossiel Fatma,Coleman Rob,Dowsett Mitch,Forbes John F,Howell Anthony,Eastell Richard

Funder

Cancer Research UK

National Health and Medical Research Council Australia

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause;Sowers;J Clin Endocrinol Metab,2010

2. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial;Cummings;JAMA,1998

3. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures;Black;Lancet,1996

4. Bone loss and fracture risk associated with cancer therapy;Guise;Oncologist,2006

5. Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia;Leslie;Nucl Med Commun,1995

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial;Journal of Clinical Oncology;2024-07-02

2. Endocrine consequences of breast cancer therapy and survivorship;Climacteric;2024-06-12

3. Changes in body composition in early breast cancer patients treated with aromatase inhibitors;Journal of Endocrinological Investigation;2024-06-10

4. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study;HEALTH TECHNOL ASSES;2024

5. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study;Breast Cancer Research and Treatment;2024-04-01